

SUPPLEMENTAL MATERIAL

Title: Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potentially neutralising monoclonal antibodies targeting distinct epitopes

Table S1. Screen for flavivirus neutralising antibodies in VRC320 study prior to vaccination


GROUP1	DENV1	DENV2	DENV3	DENV4	ZIKV	GROUP2	DENV1	DENV2	DENV3	DENV4	ZIKV	GROUP3	DENV1	DENV2	DENV3	DENV4	ZIKV
101						201						301					
102						202						302					
103						203						303					
104						204						304					
105						205						305					
107						206	+	+	+	+		306					
108						207						307					
109						208	+	+	+	+		308					
110						209						309					
111						210						311					
112	+	+	+	+	+	211						312	+	+	+		
113						212						313					
114						213						314					
115						214						315					
						215											

Table S2. Calculated sdFRNT50 values for ZIKV in VRC320 v2 samples

VCR320 101	8.6	VCR320 101	12.8	VCR320 101	1.8
VCR320 102	9.2	VCR320 102	14.6	VCR320 102	1.1
VCR320 103	18.5	VCR320 103	7.3	VCR320 103	8.8
VCR320 104	8.9	VCR320 104	0.0	VCR320 104	7.0
VCR320 105	8.9	VCR320 105	1.7	VCR320 105	0.0
VCR320 106	21.6	VCR320 206	29.5	VCR320 307	4.2
VCR320 107	6.5	VCR320 207	18.4	VCR320 308	16.8
VCR320 108	1.0	VCR320 208	34.4	VCR320 309	9.1
VCR320 109	5.1	VCR320 209	0.0	VCR320 310	8.1
VCR320 111	0.0	VCR320 210	3.1	VCR320 311	2.5
VCR320 112	72.6	VCR320 211	34.0	VCR320 312	22.0
VCR320 113	13.7	VCR320 212	20.5	VCR320 313	24.1
VCR320 114	4.8	VCR320 213	0.0	VCR320 314	10.5
VCR320 115	3.1	VCR320 214	0.0	VCR320 315	7.4
		VCR320 215	6.9		

Figure S1. Optimising serum concentration for A9E and G9E BOB

A



B







Figure S2. sdFNRT50 screening of VCR320 pre-vaccine sera for DENV neutralising antibodies




20191018 FRNT_VRC320_V2_D3




CTL

20191018 FRNT_VRC320_V2_D4



CTL

Figure S3. A9E and G9E %BOB measured in longitudinal samples from VRC320



D

